Patient Financial News

Eli Lilly’s weight loss drug, Zepbound, has been shown to lead to more significant weight loss than Novo Nordisk’s Wegovy, according to results from a new clinical trial. The study, funded by Lilly, is the first to compare the two drugs directly, providing valuable insights into their efficacy for weight loss. Lilly announced the results on Wednesday, claiming that Zepbound outperforms Wegovy, which has been a leader in the weight loss market.

Subscribe to enjoy similar stories. In the first head-to-head test, Eli Lilly’s Zepbound obesity drug helped people lose significantly more weight than its main competitor, Novo Nordisk’s Wegovy. People taking Zepbound lost 20.2% of their body weight on average after 72 weeks of treatment in the Lilly-sponsored study, compared with a 13.7% loss for Wegovy patients, Lilly said Wednesday.

Artificial intelligence is changing the way industries do business

Subscribe to enjoy similar stories. The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds competition to a market currently controlled by Eli Lilly and Novo Nordisk, it also reinforces the dominance of the makers of Wegovy and Zepbound.

«We have issued a notification that from today till an indefinite time we will not admit any Bangladeshi patient for treatment. This is primarily because of the insults they have shown towards India,» said hospital official Subhranshu Bhakt. He urged other hospitals in the city to do the same as a mark of protest against the alleged atrocities on minorities in Bangladesh.

1 Common forms of diabetes related heart risks: The commonest form of heart disease is coronary artery disease (CAD), which presents as heart attacks. Diabetes damages the blood vessels of the heart.2 Almost 75% of patients with diabetes die due to cardiac disease. Every 1% increase in hemoglobin A1c (HbA1c) above 6.5, increases the risk of CAD by 11%.2 In people with diabetes, death due to heart disease increases by 40% for every 5-unit increase in BMI above 25.2 Diabetes increases a person's risk of developing heart failure, a serious condition in which the heart is unable to pump enough blood1. Hospitalisation for heart failure is twice as common in people who are diabetic than it is in non-diabetics.2

Referring to an order issued by the Municipal Corporation of Delhi on Wednesday, the sources said that the 72-year-old man from west Delhi was admitted to the All India Institute of Medical Sciences on November 3 following chest pain. The patient is diabetic (20 years, uncontrolled), has coronary artery disease with CHF, bilateral lower limb weakness and bowel and bladder incontinence, the source said.

Dr Reddy's Laboratories on Thursday said it has launched Toripalimab, a drug for the treatment of recurrent or metastatic nasopharyngeal carcinoma in India. Nasopharyngeal carcinoma (NPC) is a rare, aggressive form of head and neck cancer that originates in the nasopharynx, the upper part of the throat. The company has launched Toripalimab, a new biological entity (NBE), Dr Reddy's Laboratories said in a regulatory filing. The medication is the only immuno-oncology drug approved by various regulatory authorities around the world such as the US Food and Drug Administration (USFDA), European Medicines Agency (EMA), Medicines and Healthcare products Regulatory Agency (MHRA), and others for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC), it added.

Subscribe to enjoy similar stories. Dr. Edward Scolnick figures he needs five, maybe 10 more years to solve one of the brain’s greatest mysteries.

oncologists questioned his claim that a strict diet helped his wife defeat stage 4 cancer, Congress leader Navjot Singh Sidhu Monday clarified that the diet plan was implemented in consultation with doctors and should be considered «facilitation in the treatment». During a press conference in Amritsar on November 21, Sidhu stated that his wife Navjot Kaur Sidhu had been declared cancer-free, emphasizing the role of dietary and lifestyle changes in her recovery. However, oncologists at Tata Memorial Hospital, Mumbai warned that cancer patients should not delay or stop their treatment by following unproven remedies. In a video message posted on X on Monday, Sidhu said, «I want to say that a doctor is like God to me, and doctors have always been my priority. I have a doctor (Navjot Kaur Sidhu) at home. Whatever we have done was done with the consultation of doctors in a collaborative process.»

The X account for internet entrepreneur Kim Dotcom says he has suffered a “serious stroke.”

Society of Jesus, or Jesuits, wanted to use this hot new technology — just over a century old — to spread Christianity in the East. This press was meant for Abyssinia (Ethiopia), but the winds took it round Africa and up to India, where it docked in Goa. It was getting ready to sail again, when it was learned that the Abyssinian emperor no longer wanted it. Francis Xavier, one of the Jesuits’s founders, had established a strong presence in Goa. So, when this news came, the Jesuits quickly set up the press. Printing using carved surfaces may have existed in India before this, but this press produced the first Indian books using movable type. This was in Roman script, but attempts were made to cast types in Indian scripts, first Tamil and then Devanagari. The earliest texts were religious, but in 1563, the press printed a book whose title translates as Colloquies on the Simples and Drugs of India (1563). Written by physician and naturalist Garcia da Orta in the form of dialogues with a fictional friend named Ruano, it describes the useful plants of India. Through the conversations, which include visits to patients, a fascinating picture emerges of the trading world of India and the Arabian Sea.

Subscribe to enjoy similar stories. Kait Handler spent much of her life in a battle with food noise. It started in childhood when she would “shame eat" packets of Devil’s Food cookies after school and hide the wrappers.

Most people taking popular drugs like Ozempic and Wegovy to lose weight have shed significant pounds

MoU with Bengaluru-based Ajit Isaac Foundation (AIF) to provide assistance in setting up and launching palliative care centres in India. These centres aim to provide “compassionate, dignified care to terminally ill patients in underserved regions in India, along with training and supporting community-based caregivers,” the parties said in a statement. AIF will establish a 63-bed Palliative Care Centre in Tumkur–neighbouring Bengaluru by early next year. This Centre will serve as the foundation for the JHU-AIF collaboration, which aims to design and implement comprehensive training programmes in palliative care, offered both online and offline, with mentorship support for staff. “JHU will help in developing a research fellowship and designing curriculum. Additionally, AIF and JHU will jointly host workshops and conferences, both in India and internationally, to showcase the latest advancements in palliative care, fostering knowledge exchange and the adoption of best practices,” AIF said in a statement.

OneCell Diagnostics raised $16 million in an oversubscribed series A funding round led by Celesta Capital. Other participants in the funding round included Tenacity Ventures, Cedars Sinai, Eragon, and Singularity Ventures. The company, which has developed cutting-edge technology for precision oncology liquid biopsy diagnostics and is headquartered in India and Silicon Valley, said the funding will be used to advance its vision of democratising precision oncology through cancer diagnostic testing that is more accessible, actionable, and affordable.

Thousands of University of California workers on Wednesday began a two-day strike to protest what they say are unfair bargaining tactics by the university system

Experts say people shopping for health insurance right now should look beyond price when searching for coverage for next year

air pollution continues to wreak havoc, the respiratory segment is expected to grow further in the coming months. While the domestic pharma market is largely driven by anti-diabetics and cardiac therapies, respiratory therapies are expected to lead the growth in November, December and January, pharma experts said. According to market research firm Pharmarack, the respiratory segment is valued at ₹16,413 crore, growing at a compound annual rate of 12%. The anti-asthma and COPD (chronic obstructive pulmonary disease) products have grown from ₹6,094 crore MAT (moving annual turnover) value in October 2021 to ₹9,960 crore in October 2024. Likewise, the cough and cold market has grown from ₹2,926 crore MAT value to ₹4,129 crore during the same period. «The respiratory market shows the normal seasonal trend for the anti-asthma and cough and cold segment,» said Sheetal Sapale, VP, commercial, Pharmarack. «There were fewer reported cases in October 2024 compared to October 2023, hence there is de-growth in the market. The market peaks in December and January and then gradually subsides as winter loses its intensity,» Sapale said.

RML started a pollution clinic last year. However, this year the number of patients is already up, highlighting the severity of air pollution across North India, especially the capital city, New Delhi. «We are seeing patients with breathlessness, blocked nose, itching in eyes and sore throat post Diwali,» said Dr Amit Jindal, consultant in respiratory medicine, RML hospital. «In the last few weeks, we are seeing a significant increase in respiratory complaints like asthma, chronic obstructive pulmonary disease (COPD), and bronchitis. „The number of patients are going up, already its more than last year,“ added Dr Ajay Shukla, Medical Superintendent, RML hospital.